Bifidobacterium longum 관련 Irritable Bowel Syndrome (IBS)
BRCTs demonstrate significant reduction in IBS composite symptom score versus placebo. Particular benefit for bloating and abdominal distension. Marketed as Alflorex/Align.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dbifidobacterium\u002Dlongum\u0026condition\u003Dibs';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
B
결론
RCTs demonstrate significant reduction in IBS composite symptom score versus placebo. Particular benefit for bloating and abdominal distension. Marketed as Alflorex/Align.
Key Study Findings
Meta-Analysis
n=3154
Comparative effectiveness and safety of probiotics with psychotropic potential in mental health benefits in irritable …
Dose: None
vs: placebo
Outcome: quality of life, depression, and anxiety in IBS …
효과: SUCRA=89.7% (B. longum for QoL); SUCRA=95.6% (probiotic combo for depression)
None
대상 집단: patients with irritable bowel syndrome
Meta-Analysis
Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome.
Dose: None
vs: placebo
Outcome: improvement in key IBS symptoms
효과: None
None
대상 집단: patients with IBS from 32 RCTs evaluating 10 probiotic strains
In Vitro
n=35
A Probiotic Mixture of Lactobacillus rhamnosus LR 32, Bifidobacterium lactis BL 04, and Bifidobacterium longum …
Dose: 1e6 CFU/mL
vs: IBS supernatants without probiotic
Outcome: Caco-2 paracellular permeability
효과: None
<0.001
대상 집단: IBS patients (28) and asymptomatic controls (7)
Review
The Role and the Regulation of NLRP3 Inflammasome in Irritable Bowel Syndrome: A Narrative Review.
Dose: None
vs: None
Outcome: IBS symptom management via NLRP3 inhibition
효과: None
None
대상 집단: Patients with IBS (narrative review)
Controlled Clinical Trial
n=51
12 weeks
Open-label
Targeted probiotic therapy in irritable bowel syndrome: a clinical evaluation on Clostridium butyricum CBM588 and …
Dose: None
vs: Pre-treatment baseline
Outcome: IBS-SSS score reduction
효과: None
None
대상 집단: IBS-D and IBS-C patients
Observational Study
n=37
8 weeks
Open-label
An 8-Week Course of Bifidobacterium longum 35624® Is Associated with a Reduction in the Symptoms …
Dose: None
vs: None
Outcome: Total IBS symptom score (TISS)
효과: 43.4% TISS reduction; >60% >=30% responders
None
대상 집단: Adults with IBS (Rome IV criteria)
Key Statistics
4
연구
600
참여자
↑
Positive
B
등급
Referenced Papers
European journal of …
2026
Journal of clinical …
2026
An 8-Week Course of Bifidobacterium longum 35624® Is Associated with a Reduction in the Symptoms of Irritable Bowel Syndrome.
Observational
Probiotics and antimicrobial …
2025
6 인용
The Role and the Regulation of NLRP3 Inflammasome in Irritable Bowel Syndrome: A Narrative Review.
Review
Microorganisms
2025
4 인용
International journal of …
2025
4 인용
Frontiers in medicine
2025
3 인용
Gut microbes
2024
22 인용
Nutrients
2024
13 인용
Microbiology spectrum
2024
9 인용
Journal of neurogastroenterology …
2024
4 인용
Journal of clinical …
2024
4 인용
Effects of Bifidobacterium longum 35624 in Children and Adolescents with Irritable Bowel Syndrome.
Other
Nutrients
2024
4 인용
Gut microbes
2024
Journal of translational …
2023
30 인용
Food & function
2023
18 인용
Neurogastroenterology and motility
2023
16 인용
Journal of gastroenterology …
2023
11 인용
Terapevticheskii arkhiv
2023
3 인용
Voprosy pitaniia
2023
Effect of Bifidobacterium longum 35624 on disease severity and quality of life in patients with irritable bowel syndrome.
Observational
World journal of …
2022
27 인용
Journal of neurogastroenterology …
2022
21 인용
Journal of microbiology …
2022
15 인용
Computational and structural …
2022
15 인용
Scientific reports
2022
14 인용
Terapevticheskii arkhiv
2022
6 인용
Microorganisms
2021
47 인용
Nutrients
2021
36 인용
Clinical nutrition ESPEN
2021
11 인용
Voprosy pitaniia
2021
3 인용
Gastroenterology
2020
290 인용
European journal of …
2020
80 인용
Nutrients
2020
78 인용
Nutrients
2020
59 인용
Gut microbes
2020
36 인용
Journal of clinical …
2020
31 인용
The Cochrane database …
2020
14 인용
Nutrients
2019
114 인용
Beneficial microbes
2019
31 인용
Journal of neurogastroenterology …
2018
121 인용
Saudi journal of …
2018
41 인용
Effectiveness of Probiotics in Children With Functional Abdominal Pain Disorders and Functional Constipation: A Systematic Review.
Systematic Review
Journal of clinical …
2018
34 인용
Gastroenterology
2018
23 인용
Gastroenterology
2017
684 인용
The Australian and …
2017
280 인용
Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis.
Meta-Analysis
Current medical research …
2017
86 인용
Journal of gastroenterology …
2017
32 인용
Current medical research …
2017
21 인용
PloS one
2016
83 인용
Artificial cells, nanomedicine, …
2016
16 인용
Journal of gastroenterology …
2014
164 인용
Orvosi hetilap
2014
6 인용
Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis.
Meta-Analysis
Revista espanola de …
2013
102 인용
Journal of clinical …
2012
207 인용
Acta bio-medica : …
2006
41 인용
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
일반적으로 사용되는 용량
- general:
- 1-10 billion CFU/day
- ibssupport:
- 1 billion CFU/day (35624 strain, marketed as Alflorex/Align)
상한량: Well-tolerated up to 10 billion CFU/day in clinical trials
연구에서 사용된 용량
| 용량 | 기간 | 효과 | N |
|---|---|---|---|
| None | -- | Positive | 3154 |
| None | -- | Positive | -- |
| 1e6 CFU/mL | -- | Positive | 35 |
| None | -- | Positive | -- |
| None | 12 weeks | Positive | 51 |
| None | 8 weeks | Positive | 37 |
| 1x10^10 CFU daily | 6 weeks | Positive | 35 |
| 2 g | 4 weeks | Mixed | -- |
권장 복용 시간: On an empty stomach or before meals
Safety & Side Effects
보고된 부작용
- ⚠ Mild gas and bloating during initial use
- ⚠ Occasional abdominal discomfort
- ⚠ Rare loose stools
- ⚠ Very rare: bacteremia in immunocompromised individuals
알려진 상호작용
- ● Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
- ● Immunosuppressants (use with caution in immunocompromised patients)
일일 최대 섭취 허용량: Well-tolerated up to 10 billion CFU/day in clinical trials
건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.
Frequently Asked Questions
Does Bifidobacterium longum help with Irritable Bowel Syndrome (IBS)?
Based on 4 studies with 600 participants, there is moderate evidence from clinical studies that Bifidobacterium longum may support Irritable Bowel Syndrome (IBS) management. Our evidence grade is B (Good Evidence).
How much Bifidobacterium longum should I take for Irritable Bowel Syndrome (IBS)?
Studies have used various dosages. A commonly studied range is 1-10 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Bifidobacterium longum?
Reported side effects may include Mild gas and bloating during initial use, Occasional abdominal discomfort, Rare loose stools, Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Bifidobacterium longum and Irritable Bowel Syndrome (IBS)?
We rate the evidence as Grade B (Good Evidence). This rating is based on 4 peer-reviewed studies with 600 total participants. The overall direction of effect is positive.
Related Evidence
관련 다른 성분: Irritable Bowel Syndrome (IBS)
FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.